University of Patras
Φαρμακοκινητική, φαρμακοδυναμική και φαρμακογενωμική ανάλυση της μπεβασιζουμάμπης σε ασθενείς με μεταστατικό καρκίνο του παχέος εντέρου
Abstract
dc:descriptionThe benefit of bevacizumab in the treatment of different tumors has been established in several studies. However, clinical outcomes had variability, with some patients responding remarkably well, while others not. Pharmacokinetic parameters are among the most important parameters which influence the drug action and clinical response.To evaluate the effect of various physiological, pharmacokinetic, pharmacodynamic and genetic factors on clinical results in patients receiving first-line treatment of metastatic colorectal cancer with bevacizumab plus chemotherapy and their predictability, a prospective non-interventional observational study conducted. A total of 46 patients with confirmed colon cancer stage 4, who received first-line treatment with bevacizumab plus chemotherapy were included in this study. The patient's integration process in the study lasted one year. The follow-up of patients after their integration was five years.Τreatment response, progression free survival and overall survival was assessed and concentration of total bevacizumab and free VEFG165 in serum was determined. Detection of VEG-A and ICAM-1 mononucleotide polymorphisms in whole blood and of KRAS, NRAS and BRAF genes in tumor tissue sample were also detected.Treatment response was unaffected by any VEGF-A, ICAM-1, KRAS and NRAS polymorphism. In contrast, mutations in BRAF were statistically significant (p = 0.026) with no response to treatment. Patients homozygous for VEGF-A rs699947 A / A showed statistically significant prolonged PFS and OS in comparison to patients presenting the wild-type C / C form of the gene.With regard to the ICAM-1 gene, patients carrying the rs1799969 G / A allele showed statistically significantly increased OS compared to carriers of G / G allele. Concerning the BRAF gene, patients with tumors with the wild-type of the gene were found to have statistically significantly prolonged survival compared to patients who had mutant BRAF.Strong negative correlation was observed between total bevacizumab levels and its molecular target VEGF165. The factor that primarily affected the binding model was the VEGF-A rs699947 A / A allele (p = 0.002). Finally, it was observed that higher bevacizumab concentrations were significantly associated with increased OS (p=0.0003).If these findings were confirmed by further studies, these biomarkers could be incorporated and used to select patients with mCRC, who could benefit from bevacizumab-based therapies.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papachristos, Apostolos
- Παπαχρήστος, Απόστολος
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- BY_NC
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45842